Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes.

摘要: Recent advances in our understanding of the molecular biology gastric and oesophageal cancers have shown that gastroesophageal adenocarcinoma should be considered as one disease spectrum. Clinical management these is challenging, with poor outcomes both early late settings. Certain subsets demonstrate features suggest immunotherapy could an effective treatment. Immunogenetic markers, including mismatch repair deficiency, PD-L1 status tumour infiltrating lymphocytes influence overall prognosis. They may also determine response to adjuvant neoadjuvant conventional chemotherapy. Initial results from trials for cancer however been mixed, responses first- second-line This review aims discuss how better immune genetic interactions lead selection patients based therapies, therefore improve patient outcomes. We challenges implementing this new routine practice, current limitations treatments cancer.